DRTSAlpha Tau Medical Ltd.

Nasdaq alphatau.com


$ 2.63 $ -0.08 (-2.95 %)    

Thursday, 23-May-2024 09:31:00 EDT
QQQ $ 454.82 $ -7.90 (-1.71 %)
DIA $ 398.57 $ -6.29 (-1.58 %)
SPY $ 530.36 $ -7.40 (-1.39 %)
TLT $ 91.26 $ -0.63 (-0.69 %)
GLD $ 225.37 $ -3.23 (-1.47 %)
$ 2.71
$ 2.63
$ 0.00 x 0
$ 0.00 x 0
$ 2.63 - $ 2.63
$ 2.15 - $ 4.80
24,768
na
188.81M
$ 1.47
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-alpha-tau-medical-maintains-9-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $9 price target.

 alpha-tau-medical-q1-eps-011-beats-012-estimate

Alpha Tau Medical (NASDAQ:DRTS) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0...

 hc-wainwright--co-reiterates-buy-on-alpha-tau-medical-maintains-9-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $9 price target.

 alpha-tau-presents-preclinical-data-demonstrating-abscopal-immune-effect-in-pancreatic-murine-tumor-models-at-estro-2024-congress-in-glasgow-initial-data-demonstrates-reduction-in-distant-pancreatic-cancer-tumor-growth-rate-starting-from-3-weeks-after-first-tumor-is-treated-with-alpha-dart-alone

- Initial data demonstrates significant reduction in distant pancreatic cancer tumor growth rate starting from three weeks afte...

 hc-wainwright--co-reiterates-buy-on-alpha-tau-medical-maintains-9-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $9 price target.

 piper-sandler-reiterates-overweight-on-alpha-tau-medical-lowers-price-target-to-7

Piper Sandler analyst Jason Bednar reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Overweight and lowers the price target ...

 citigroup-initiates-coverage-on-alpha-tau-medical-with-buy-rating-announces-price-target-of-8

Citigroup analyst Ashiq Mubarack initiates coverage on Alpha Tau Medical (NASDAQ:DRTS) with a Buy rating and announces Price...

 alpha-tau-announces-interim-results-from-safety-and-feasibility-trial-of-alpha-dart-treatment-of-advanced-pancreatic-cancer

- Interim data read-out of the first five treated patients demonstrated successful delivery in all five cases, as well as no pr...

 alpha-tau-submits-to-japanese-pmda-for-pre-market-approval-of-alpha-dart-in-patients-with-recurrent-head-and-neck-cancer

Alpha Tau Medical Ltd. ("Alpha Tau") (NASDAQ:DRTS, DRTSW)))), the developer of the innovative alpha-radiation cancer th...

 hc-wainwright--co-reiterates-buy-on-alpha-tau-medical-maintains-9-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $9 price target.

 piper-sandler-maintains-overweight-on-alpha-tau-medical-lowers-price-target-to-8

Piper Sandler analyst Jason Bednar maintains Alpha Tau Medical (NASDAQ:DRTS) with a Overweight and lowers the price target f...

 alpha-tau-medical-9m-eps-031
Alpha Tau Medical 9M EPS $(0.31)
11/16/2023 21:36:59

 alpha-tau-enters-into-long-term-lease-of-site-in-new-hampshire-for-second-us-manufacturing-facility

Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)))), the developer of the innovative...

 hc-wainwright--co-reiterates-buy-on-alpha-tau-medical-maintains-9-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $9 price target.

 alpha-tau-medical-says-a-patient-with-advanced-inoperable-pancreatic-cancer-using-its-alpha-radiation-cancer-therapy-alpha-dart-has-been-treated-in-a-clinical-trial-at-hadassah-medical-center-in-israel

The trial is designed for a broad range of solid tumor patients who do not qualify for participation in other existing trials o...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION